---
document_datetime: 2025-11-10 10:47:41
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/dectova-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: dectova-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.2966055
conversion_datetime: 2025-12-28 12:25:08.593368
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## DECTOVA

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                            |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 10/11/2025                          |                                             | SmPC, Annex                      | To update Section 7 of the SmPC, Section 11 of the |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000308615                          | PRODUCTS - C.I.z Other variation - Accepted C.I.z (Type IB) - To update Section 7 of the SmPC, Section 11 of the Labelling and Section 6 of the Package Leaflet by adding the Postal Code to the MAH address. In addition, the MAH took the opportunity to implement editorial changes by: (1) correcting typographical errors throughout the Product Information, (2) deleting the local representative for UK(NI) in line with the QRD template, (3) updating the details of the local representative for IS, (5) updating the links to Appendix V in line with the QRD template, and (6) deleting the manufacturer \"Glaxo Operations UK Ltd\" in the HR Package Leaflet.   |            | II, Labelling and PL   | Labelling and Section 6 of the Package Leaflet by adding the Postal Code to the MAH address. In addition, the MAH took the opportunity to implement editorial changes by: (1) correcting typographical errors throughout the Product Information, (2) deleting the local representative for UK(NI) in line with the QRD template, (3) updating the details of the local representative for IS, (5) updating the links to Appendix V in line with the QRD template, and (6) deleting the manufacturer \"Glaxo Operations UK Ltd\" in the HR Package Leaflet.   |
|--------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Annual reassessment - H / EMA/S/0000265004 | - Annual Reassessment - Accepted 6th annual re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 20/08/2025 | Annex II               | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of DECTOVA should be maintained. Annex II of the PI is amended to update the due date for SOB1.                                                                                                                                                                                                                             |